Shanghai Rendu Biotechnology Co., Ltd. (SHA:688193)
China
· Delayed Price · Currency is CNY 35.20
-0.24 (-0.68%)
At close: Apr 25, 2025, 2:57 PM CST
SHA:688193 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Operating Revenue | 177.35 | 162.76 | 293.94 | 286.13 | 247.23 | Upgrade
|
| Other Revenue | - | 1.65 | 9.91 | 6.18 | 2.67 | Upgrade
|
| Revenue | 177.35 | 164.41 | 303.85 | 292.31 | 249.9 | Upgrade
|
| Revenue Growth (YoY) | 7.87% | -45.89% | 3.95% | 16.97% | 152.00% | Upgrade
|
| Cost of Revenue | 36.38 | 31.89 | 106.11 | 74.38 | 60.76 | Upgrade
|
| Gross Profit | 140.97 | 132.53 | 197.74 | 217.93 | 189.14 | Upgrade
|
| Selling, General & Admin | 119.27 | 118.31 | 155.04 | 127.4 | 102.3 | Upgrade
|
| Research & Development | 39.17 | 40.54 | 33.89 | 26.12 | 23.18 | Upgrade
|
| Other Operating Expenses | -5.36 | -0.69 | 0.86 | 0.83 | -4.6 | Upgrade
|
| Operating Expenses | 153.07 | 158.76 | 192.72 | 155.35 | 121.61 | Upgrade
|
| Operating Income | -12.09 | -26.23 | 5.02 | 62.58 | 67.53 | Upgrade
|
| Interest Expense | - | -0.43 | -0.36 | -0.26 | -0.09 | Upgrade
|
| Interest & Investment Income | 11.17 | 15.65 | 12.57 | 3.21 | 1.54 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.12 | 0.56 | -0.2 | -0.28 | Upgrade
|
| Other Non Operating Income (Expenses) | -11.48 | -0.06 | 0.13 | -0.15 | 1.32 | Upgrade
|
| EBT Excluding Unusual Items | -12.4 | -11.19 | 17.93 | 65.18 | 70.02 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.24 | 0.66 | 0.98 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.14 | -0.05 | 0.14 | 0.76 | 0.51 | Upgrade
|
| Asset Writedown | -2.72 | -0.34 | -1.19 | -0.38 | -0.29 | Upgrade
|
| Other Unusual Items | - | 15.69 | 8.82 | 6.89 | - | Upgrade
|
| Pretax Income | -15.22 | 4.76 | 26.68 | 72.44 | 70.24 | Upgrade
|
| Income Tax Expense | -7.41 | -3.5 | 3.35 | 7.82 | 8.87 | Upgrade
|
| Net Income | -7.81 | 8.26 | 23.33 | 64.62 | 61.38 | Upgrade
|
| Net Income to Common | -7.81 | 8.26 | 23.33 | 64.62 | 61.38 | Upgrade
|
| Net Income Growth | - | -64.60% | -63.89% | 5.28% | 1541.45% | Upgrade
|
| Shares Outstanding (Basic) | 39 | 39 | 38 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 39 | 39 | 38 | 30 | 30 | Upgrade
|
| Shares Change (YoY) | -0.68% | 2.83% | 26.08% | 0.95% | 0.65% | Upgrade
|
| EPS (Basic) | -0.20 | 0.21 | 0.62 | 2.15 | 2.05 | Upgrade
|
| EPS (Diluted) | -0.20 | 0.21 | 0.61 | 2.13 | 2.04 | Upgrade
|
| EPS Growth | - | -65.57% | -71.36% | 4.41% | 1528.92% | Upgrade
|
| Free Cash Flow | 13.86 | -3.2 | -25.31 | 27.97 | 77.06 | Upgrade
|
| Free Cash Flow Per Share | 0.35 | -0.08 | -0.66 | 0.92 | 2.56 | Upgrade
|
| Dividend Per Share | - | 0.200 | 0.125 | - | - | Upgrade
|
| Dividend Growth | - | 60.00% | - | - | - | Upgrade
|
| Gross Margin | 79.49% | 80.61% | 65.08% | 74.56% | 75.69% | Upgrade
|
| Operating Margin | -6.82% | -15.95% | 1.65% | 21.41% | 27.02% | Upgrade
|
| Profit Margin | -4.41% | 5.02% | 7.68% | 22.11% | 24.56% | Upgrade
|
| Free Cash Flow Margin | 7.82% | -1.94% | -8.33% | 9.57% | 30.84% | Upgrade
|
| EBITDA | 2.25 | -13.43 | 17.42 | 70.93 | 73.32 | Upgrade
|
| EBITDA Margin | 1.27% | -8.17% | 5.73% | 24.27% | 29.34% | Upgrade
|
| D&A For EBITDA | 14.34 | 12.8 | 12.4 | 8.35 | 5.79 | Upgrade
|
| EBIT | -12.09 | -26.23 | 5.02 | 62.58 | 67.53 | Upgrade
|
| EBIT Margin | -6.82% | -15.95% | 1.65% | 21.41% | 27.02% | Upgrade
|
| Effective Tax Rate | - | - | 12.56% | 10.80% | 12.62% | Upgrade
|
| Revenue as Reported | - | 164.41 | 303.85 | 292.31 | 249.9 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.